Form 4: Eli Lilly Director Acquires Shares Through Deferral Plan

Director Ralph Alvarez acquired 16 shares of Eli Lilly common stock through a deferral plan, as reported in a recent SEC filing.

Summary

• Ralph Alvarez, a director at Eli Lilly & Co, acquired 16 shares of common stock on February 20, 2024.
• The shares were acquired at a price of $755.66 each.
• This transaction was part of the Lilly Directors' Deferral Plan, where the shares are deferred in lieu of cash compensation.
• The shares will be settled in common stock after Mr. Alvarez's separation from service.
• Following this transaction, Mr. Alvarez directly owns 53,906 shares of Eli Lilly common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The transaction is a routine insider activity, but the acquisition of shares by a director can be seen as a sign of confidence in the company.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Future Outlook

The acquired shares will be settled in common stock following the reporting person's separation from service.

Industry Context

This is a routine filing related to insider transactions and is common for publicly traded companies. It reflects a director's participation in a company's deferral plan.

Comparison to Industry Standards

• Director share acquisitions through deferral plans are a common practice among publicly traded companies, particularly in the pharmaceutical industry.
• Many companies offer similar deferral plans to align the interests of directors with those of shareholders.
• The specific terms of deferral plans can vary, but the general concept of deferring compensation into company stock is widely used.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it indicates a director's confidence in the company.

Key Dates

Keywords

Eli Lilly, LLY, Director, Share Acquisition, Deferral Plan, SEC Form 4, Insider Trading, Stock Ownership